论文部分内容阅读
目的本研究旨在了解肝肠源性螺杆菌是否存在于肝细胞癌患者的胆汁内,探讨此菌与肝癌的相关性。方法收集经病理确诊的47例原发性肝细胞癌患者及24例结肠直肠癌肝转移患者的胆汁标本。使用特定16SrRNA引物的聚合酶链式反应(PCR)及DNA测序检测胆汁标本中的螺杆菌属及肝螺杆菌特异性16SrRNA,并使用酶联免疫吸附法(ELISA)检测胆汁标本中的肝螺杆菌抗体。结果 47例原发性肝细胞癌患者胆汁标本中有12例(25.5%)检测出肝螺杆菌特异性16SrRNA,15例(31.9%)检测出抗肝螺杆菌抗体;24例结肠直肠癌肝转移患者胆汁标本中只有1例(4.2%)检测出肝螺杆菌特异性16SrRNA基因,3例(12.5%)检测出抗肝螺杆菌抗体(P<0.05)。结论原发性肝细胞癌患者可检测出肝螺杆菌,这可能与肝细胞癌的发病机制有一定联系。
Objective This study aimed to understand whether enterohepatic Helicobacter pylori exists in patients with hepatocellular carcinoma in the bile to explore the bacteria and liver cancer. Methods Forty-seven patients with primary hepatocellular carcinoma and 24 patients with liver metastases from colorectal cancer were collected for pathological diagnosis. The specific 16SrRNAs of Helicobacter and hepaticus in bile samples were detected by polymerase chain reaction (PCR) and DNA sequencing using specific 16S rRNA primers, and Helicobacter pylori in bile samples were detected by enzyme-linked immunosorbent assay (ELISA) antibody. Results In 47 cases of primary hepatocellular carcinoma, 12 (25.5%) of the bile specimens were detected by HepG-specific 16S rRNA and 15 (31.9%) were detected anti-Helicobacter pylori antibodies. Twenty-four patients with colorectal cancer with liver metastasis Only 1 case (4.2%) of bile samples detected HepG2-specific 16S rRNA gene and 3 cases (12.5%) detected anti-Helicobacter pylori antibody (P <0.05). Conclusion Hepatitis Helicobacter can be detected in patients with primary hepatocellular carcinoma, which may be related to the pathogenesis of hepatocellular carcinoma.